Market Overview

Opportunity Outlook on the Global Benign Prostatic Hyperplasia Therapeutics Market to 2025: High Market Potential in Untapped Emerging Economies -


The "Benign
Prostatic Hyperplasia Therapeutics Market by Therapeutic Class, and
Therapy - Global Opportunity Analysis and Industry Forecast, 2018-2025"

report has been added to's

The global benign prostatic hyperplasia therapeutics market was valued
at $10,688.72 million in 2017, and is projected to reach $20,096.68
million by 2025 at a CAGR of 8.1% from 2018 to 2025.

This market is majorly driven by an increase in the male geriatric
population because the disease generally occurs in men of age 60 and
above. The other factors boosting the market growth include growth in
awareness related to urological disorders and prostate cancer and rise
in the number of global benign prostatic hyperplasia patients.

Furthermore, presence of a plethora of products in the pipeline and high
market potential in untapped emerging economies are anticipated to serve
as attractive opportunities during the forecast period.

However, preferences for minimally-invasive surgeries namely,
laparoscopic prostatectomy, transurethral needle ablation (TUNA), and
transurethral microwave thermotherapy (TUMT), hinder the growth of the
global BPH therapeutics market.

List of Key Players Profiled

  • Abbott Laboratories
  • Allergan PLC
  • Astellas Pharma Inc.
  • Boehringer Ingelheim Pharma GmbH & Co. KG
  • Eli Lilly and Company
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited

Key Topics Covered

Chapter 1: Introduction

Chapter 2: Executive Summary

Chapter 3: Market Overview

Chapter 4: Benign Prostatic Hyperplasia Therapeutics Market, by
Therapeutic Class

Chapter 5: Benign Prostatic Hyperplasia Therapeutics Market, by Therapy

Chapter 6: Benign Prostatic Hyperplasia Therapeutics Market, by Region

Chapter 7: Company Profiles

For more information about this report visit

View Comments and Join the Discussion!